Abstract:Introduction Atypical sites for thrombosis include deep vein thrombosis (DVT) of the upper extremity (UE-DVT), splanchnic vein thrombosis (SVT), and cerebral venous sinus thrombosis (CVST). In addition to specific pathogenic factors, their underlying mechanisms share similarities with typical venous thromboembolism (VTE), namely, DVT of the lower extremity and/or pulmonary embolism, but are less understood. Methods Records of unselected patients with a history of typical VTE ( n = 2,011), UE-DVT ( n = 117), SVT ( n = 83), and CVST ( n = 82), who were referred to the Institute in Bonn for ambulatory thrombophilia testing, were retrospectively analyzed. Acquired and hereditary thrombosis risk factors were comparatively assessed. Results UE-DVT was characterized by a high rate (50.4%) of site-specific acquired risk factors. Compared with typical VTE, SVT was more frequently associated with systemic inflammation, infection, or malignancy (2.2 vs. 12.0%, p = 3·10 −8 ) and the JAK2 V617F mutation was present in 16.9%. In CVST compared with typical VTE, demographics and higher rates of oral contraception (43.2 vs. 57.6%, p = 0.011) and pregnancy (4.2 vs. 10.9%, p = 0.012) suggest a significant hormonal influence on etiology. While the prevalence of inhibitor deficiencies and factor V Leiden mutation did not differ between cohorts, the prevalence of F2 20210G > A was higher in SVT (15.7%, p = 0.003) and CVST (15.9%, p = 0.003) than in typical VTE (7.0%). Conclusion The cohorts with thrombosis in atypical sites showed distinctive patterns of acquired risk factors. Further studies are warranted to provide additional mechanistic insight into the role of hormonal influence in CVST and the contribution of F2 20210G > A to the development of SVT and CVST. H.R. and S.R. are joint senior authors. H.R. and S.R. conceived and designed the study; D.K., H.L.M, N.S., and S.R. collected the data; D.K., H.R., and S.R. analyzed the data. D.K., H.R., and S.R. drafted and edited the manuscript. All authors revised the manuscript, agreed with its content, and approved of submission. J.O. has received research funding from Bayer, Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum, and Takeda; consultancy, speakers bureau, honoraria, scientific advisory board, and travel expenses from Bayer, Biogen Idec, BioMarin, Biotest, Chugai Pharmaceutical Co., Ltd., CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, F. Hoffmann-La Roche Ltd., Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum, and Takeda. The other authors declare no competing financial interests. * Heiko Rühl and Sara Reda are joint senior authors. Received: 09 April 2024 Accepted: 14 May 2024 Article published online: 26 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

EXPRESS: Inpatient Thrombophilia workup; Does Hematology consult prevent unnecessary testing?

Decision Theoretical Foundations of Clinical Practice Guidelines: an Extension of the ASH Thrombophilia Guidelines

Impact of thrombophilia on venous thromboembolism management

Thrombophilia Screening: Not So Straightforward

American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients

A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism

Do we need more guidance on thrombophilia testing? Challenges and special considerations

Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis

Venous Thromboembolism Characteristics and Outcomes Among RIETE Patients Tested & Untested for Inherited Thrombophilia

[Thrombophilia--diagnostic steps and therapeutic consequences after deep vein thrombosis]

[Diagnosis and treatment of venous thrombosis]

International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology

Management of Venous Thromboembolism: A Systematic Review for a Practice Guideline

2009 evidence-based clinical practice guidelines for diagnosing a first episode of lower extremities deep vein thrombosis in ambulatory outpatients

Danger of false negative (exclusion) or false positive (diagnosis) for ‘congenital thrombophilia’ in the age of anticoagulants

Prevention of Venous Thromboembolism during Pregnancy and the Puerperium with a Special Focus on Women with Hereditary Thrombophilia or Prior VTE—Position Paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH)

Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline

High Prevalence of F2 20210G > A in Splanchnic Vein Thrombosis and Cerebral Venous Sinus Thrombosis: A Retrospective Cohort Study of Patients with Thrombosis in Atypical Sites

Thrombophilia states and markers of coagulation activation in the prediction of pediatric venous thromboembolic outcomes: a comparative analysis with respect to adult evidence